

Societal Statements on OVA1[®] (Multivariate Index Assay)

ACOG Practice Bulletin 174, Nov. 2016

B

Level

Recommendations - Consultation with or referral to a gynecologic oncologist

Recommended for women with an adnexal mass who meet one or more of the following criteria:

Premenopausal or postmenopausal women with an elevated score on a formal risk assessment test such as the **multivariate index assay** (MIA = OVA1)

C

Level

Recommendations - Determine the need for referral when surgery is required

Serum biomarker panels may be used as an alternative to CA125 level alone in determining the need for referral to or consultation with a gynecologic oncologist when an adnexal mass requires surgery.

2016 ACOG.org Practice Bulletin 174 Evaluation and Management of Adnexal Masses

NCCN June 2016

Test helps qualify the type of surgeon needed for womens' specific needs

The OVA1 test uses 5 biomarkers (including transthyretin, apolipoprotein A1, transferrin, beta-2 microglobulin, and CA-125) to assess who should undergo surgery by an experienced gynecological oncologist and who can have surgery in the community.

2016 NCCN.org Ovarian Cancer Guidelines Version 1.2016

SGO Position Statement 2014

Multiplex serum testing for women with pelvic mass

May 2013 – *"Blood levels of five proteins in women with a known ovarian mass have been reported to change when ovarian cancer is present. Tests measuring these proteins may be useful in identifying women who should be referred to a gynecologic oncologist.*

*Recent data have suggested that such tests, along with physician clinical assessment, may improve detection rates of malignancies among women with pelvic masses planning surgery."*¹

2013 SGO.org

Ova¹

by ASPiRA LABS[®]
YOUR HEALTH. OUR PASSION.

Performance Comparison

Sensitivity by Stage²

	Stage I	Stage II	Early Stage	Pre-menopausal Early Stage	Post-menopausal Early Stage
OVA1	89%	100%	91%	91%	92%
CA-125	64%	71%	66%	46%	75%
ROMA	n/a	n/a	75%	n/a	n/a

Sensitivity Across Subtypes

	EOC	Non-EOC	Borderline/ LMP	Metastatic to ovary	Non-ovarian malignancy
OVA1²	95%	80%	82%	100%	100%
ROMA ³	94%	50%	74%	50%	61%
CA-125 ²	82%	40%	53%	100%	50%

References

1. Multiplex Serum Testing for Women with Pelvic Mass (Nov. 20, 2014) Retrieved from: <https://www.sgo.org/newsroom/position-statements-2/multiplex-serum-testing-for-women-with-pelvic-mass/>
2. Bristow RE, Smith A, Zhang Z, et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. *Gynecol Oncol.* 2013;128(2):252-259.
3. Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. *Obstet Gynecol.* 2011;118(2 Pt 1):280-288.

